Recaticimab
As of the edition of 20 October 2026, Recaticimab is an antibody: in active development; acts on PCSK9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2020
- Kind
- Antibody
- Registered trials
- 18, 0 stopped early
- Disease areas
- Nutrition and metabolism; Heart and blood vessels; Nervous system; Inherited and neonatal; Cancer; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PCSK9 | Proprotein convertase subtilisin/kexin type 9 | Q8NBP7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 5 | 1 | 3 | 0 |
| Phase 3 | 5 | 3 | 2 | 0 |
| Phase 4 | 6 | 0 | 6 | 0 |
| All trials | 18 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2018 to now |